Mogamulizumab is an anti-CCR4 mAb that has been approved for the treatment of T-cell lymphomas mycosis fungoides and Sézary syndrome, two of the most common T-cell lymphomas [301]. The gene discussed is CCR4; the disease is T-cell non-Hodgkin lymphoma.